1. Introduction {#sec1}
===============

Allergic rhinitis (AR) is a common pediatric chronic upper respiratory disease worldwide, which affects 10% to 20% of the children, and its prevalence has significantly increased over the last two decades \[[@B1]\]. Medical treatment may achieve good effect, but the improvement does not last long enough after the medicine was withdrawn.

Allergy immunotherapy (AIT) is effective for both allergic asthma and rhinitis by modifying the natural course of allergic disease and inducing allergen-specific immune tolerance \[[@B2]\]. The safety and efficacy of both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) has been confirmed by several double-blind, placebo-controlled trials and meta-analyses \[[@B3]--[@B5]\].

Despite good efficacy, some patients discontinue or reject SLIT because the treatment is slow onset, is long-lasting, and has no surveillance like SCIT. A poor compliance is a general challenge for prolonged medical treatments. On the other side, a good compliance often comes from rapid onset and good short-term efficacy of SLIT. However, few studies have been conducted in the short-term efficacy of SLIT treatment \[[@B6]\].

Therefore, there is an urgent need for identifying predictors for short-term efficacy of SLIT-responsive and SLIT-nonresponsive endotypes. With these predictors, doctors can select patients who are most likely to be responsive to SLIT; thus, the SLIT efficacy and compliance could be significantly enhanced.

In this study, we report the short-term efficacy of 517 children who underwent SLIT. The clinical characteristics and laboratory parameters were analyzed for the prediction of short-term efficacy of SLIT, and receiver operating characteristic (ROC) curves were used to determine the sensitivity, specificity, and predicted values for target predictors.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

A total of 517 children with AR that underwent SLIT between June 2017 and June 2019 were enrolled. The diagnosis of AR was defined according to ARIA criteria, and the typical symptom was recorded \[[@B1]\]. Allergic status was confirmed by the prick test or specific IgE (s-IgE) for Dermatophagoides farinae (Der f). We excluded the children allergic to other allergens. All the children had no history of asthma, atopic dermatitis, or other systematic diseases. The study was approved by the local ethical committee, and the written informed consent was provided.

Baseline information such as sex, age, body weight, height, parental allergic history, passive smoke history, daily diet, living environment, physical activity, disease duration, and severity were collected at the beginning of the study. The air conditioner is often used for 10 to 15 hours depending on the weather condition, and the temperature is often set between 24 and 26°C.

2.2. Immunotherapy {#sec2.2}
------------------

SLIT were conducted as we previously described \[[@B7]\]. The Der f drops were provided by Wolwopharma Biotechnology Company (Zhejiang, China). According to the manufacturer\'s instruction, the children were guided to take increasing doses (No. 1, 1 mg/mL; No. 2, 10 mg/mL; and No. 3, 100 mg/mL) during the first three weeks and then were instructed to have 3 drops of No. 4 solution (No. 4, 333 mg/mL) once daily during the maintenance phase. The drops were instructed to be kept under the tongue for 2-3 minutes before being swallowed. The adverse effects related to SLIT were recorded on diary cards during the whole period.

2.3. Symptom and Medication Score and Evaluation of Efficacy {#sec2.3}
------------------------------------------------------------

The symptom and medication scores were assessed at baseline and 12 weeks and 6 months after SLIT. The nasal symptoms in the last two weeks of evaluation (runny nose, sneezing, blocked nose, and itchy nose) were recorded as follows: 0 = no symptoms, 1 = slight symptoms, 2 = moderate symptoms, and 3 = severe symptoms.

The children were allowed to use oral or nasal antihistamines and/or intranasal steroids in case of aggravated symptoms. The medication score was defined as the sum of medication use in the last two weeks (1 point for an antihistamine tablet, intranasal antihistamine; 2 points for an intranasal corticosteroid) according to the statement of the World Allergy Organization Task Force. The symptom and medication scores were recorded, and a combined Symptom Medication Score (SMS) was obtained by adding together the two scores.

The children that obtained a 30% SMS compared to their baseline score were defined as the response group.

2.4. Laboratory Parameters {#sec2.4}
--------------------------

Peripheral blood cell counts were measured by a Technicon-H1 blood cell counter (Bayer, Leverkusen, Germany). The serum total-IgE, eosinophil cationic protein (ECP), and s-IgE in serum were determined using a Unicap ECP kit (Pharmacia Diagnostics; Uppsala, Sweden) at baseline level and 12 weeks and 6 months after SLIT.

The serum levels of cytokines were determined by ELISA kits (R&D systems, USA) as the instructions provided by manufacturer. The sensitivity for cytokines was as follows: IL-4, 0.22 pg/mL; IL-5, 3.9 pg/mL; IL-12, 5 pg/mL; IL-13, 125 pg/mL; IL-17, 62.5 pg/mL; IL-10, 62.5 pg/mL; IL-35, 62.5 pg/mL; IFN-gamma, 8 pg/mL; and TGF-*β*, 125 pg/mL.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analyses were performed with SPSS 17.0. Data were expressed as the mean and 95% confidence interval (CI) for the mean when the data distribution was normal. The two-sided *t*-test was used for group comparison. The *χ*^2^ test was used to compare categorical variables.

According to the results of the univariate analysis, the multivariate unconditional logistic regression model was used to determine the independent predicting factors for the AIT clinical response. The results were expressed as odds ratios (ORs) and their 95% CIs. For all tests, *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Baseline Information during SLIT {#sec3.1}
-------------------------------------

This study recruited 517 children, and the baseline information is reported in [Table 1](#tab1){ref-type="table"}. During the six months of treatment, 51 children dropped out from the study due to different reasons ([Table 2](#tab2){ref-type="table"}). The adverse reactions during the study are summarized in [Table 3](#tab3){ref-type="table"}, and no severe reaction was reported.

3.2. Comparison between Patients with and without Short-Term Clinical Efficacy in SLIT {#sec3.2}
--------------------------------------------------------------------------------------

As shown in [Table 4](#tab4){ref-type="table"}, the SMS after 3 and 6 months of treatment in the effective group decreased significantly. All the patients (271 children) with effective clinical responses after 3 months of treatment still reported effective clinical responses until 6 months of treatment, while 32 children received clinical responses after 6 months of treatment despite no response obtained after 3 months of treatment. In the ineffective group, the SMS was not changed after 3 and 6 months of SLIT.

Between children with and without clinical efficacy to 6 months of SLIT, significant differences were found with regard to the following characteristics: parents\' educational background, time of using the air conditioner, materials for walls, serum t-IgE levels, serum s-IgE levels, serum s-IgE/t-IgE ratios, and baseline levels of IL-10, IL-35, and TGF-beta ([Table 5](#tab5){ref-type="table"}).

3.3. Multivariate Analysis {#sec3.3}
--------------------------

Multivariate logistic regression analysis showed that the time of using the air conditioner was negatively correlated with clinical efficacy, whereas the serum-specific IgE (s-IgE) levels, the serum IL-10 and IL-35 levels, and the s-IgE/total-IgE ratio were positively correlated with clinical efficacy (Tables [6](#tab6){ref-type="table"} and [7](#tab7){ref-type="table"}).

Next, we determined the clinical significance of the serum s-IgE levels, s-IgE/t-IgE ratio, and levels of IL-10 and IL-35 for the prediction of short-term efficacy of SLIT. The AUC was 0.916 for the serum s-IgE/t-IgE ratio (95% CI, 0.862-0.971), 0.770 for serum s-IgE (95% CI, 0.660-0.879), 0.758 for serum IL-10 levels (95% CI, 0.648-0.868), and 0.776 for serum IL-35 levels (95% CI, 0.668-0.883) ([Figure 1](#fig1){ref-type="fig"}). When compared with each other, significant differences were found between the serum s-IgE/t-IgE ratio and the serum s-IgE (*P* \< 0.01), IL-10 (*P* \< 0.01), and IL-35 (*P* \< 0.01). No significant difference was found between other markers. Our ROC analysis of the serum s-IgE/t-IgE ratio showed that a ratio of greater than 12.6% had the best sensitivity (97.2%) and specificity (74.1%) to predict short-term efficacy.

4. Discussion {#sec4}
=============

The efficacy of SLIT has been proved in previous studies \[[@B4]\]. In general, rapid onset and good short-term efficacy often contribute to less dropout and good compliance. Therefore, it would be useful to search for specific predictors to determine those patients who might obtain rapid onset and best benefit from this therapy.

Previous studies reported inconsistent onset of action for HDM SLIT, ranging from 8 weeks to 6 months \[[@B7]--[@B9]\]. One randomized, placebo-controlled field trial of 120 patients that underwent SLIT assessed the onset of action as 14 weeks (the earliest measured time point was 1 week) \[[@B8]\]. In another field trial with 108 HDM SLIT subjects, the clinical effect on nasal symptoms appeared to begin at approximately 6 months \[[@B9]\]. However, the onset of action for HDM SLIT was not reported in children and most predictors were evaluated for long-term efficacy.

In the present study, we found that most children (271, 58%) received good clinical efficacy after 3 months of treatment and the response rate increased to 303 (65%) at 6 months after treatment, proving good short-term efficacy of SLIT. Besides, the treatment was safe and no severe reaction was reported.

To confirm predictors for SLIT-responsive and SLIT-nonresponsive endotypes, we compared and analyzed the clinical characteristics and laboratory parameters related to clinical efficacy. We found that parents\' educational background, time of using the air conditioner, materials for walls, serum t-IgE levels, serum s-IgE levels, serum s-IgE/t-IgE ratios, and the levels of IL-10, IL-35, and TGF-beta were correlated with clinical responses. However, multivariate logistic regression analysis showed that the clinical efficacy was significantly correlated with the time of using the air conditioner, serum s-IgE levels, and levels of IL-10 and IL-35.

Previous studies showed that Der f was found and had high concentration in the air conditioner filters. Therefore, the longer the air conditioner was used, the more severe the symptoms the patients underwent, which also led to poor clinical efficacy \[[@B10]\].

Di Lorenzo et al.\'s study reported that a significant positive correlation was found between the serum s-IgE/t-IgE ratio (\>16.2) and the clinical response \[[@B11]\]. A pediatric study found that the serum t-IgE is superior to both the serum s-IgE/t-IgE ratio and s-IgE levels alone in predicting clinical effectiveness in children with allergic asthma and/or rhinitis due to HDM \[[@B12]\]. On the contrary, Fujimura et al.\'s study suggested that patients with a low serum-specific IgE/total-IgE ratio (\<0.19) achieved better AIT benefit than patients with a higher ratio \[[@B13]\]. In the present study, we found that the serum t-IgE levels, serum s-IgE levels, and serum s-IgE/t-IgE ratios were higher in the effective group compared to the ineffective group. However, multivariate logistic regression analysis showed that the clinical efficacy was only significantly positively correlated with the serum s-IgE levels and s-IgE/t-IgE ratio. We found that the serum s-IgE/t-IgE ratio is the best predictor of clinical efficacy in SLIT.

The immunotherapy has been reported to induce downregulation of the Th2 response with a shift toward a Th1 cytokine profile \[[@B14]\]. Moreover, upregulation of iTregs may be considered prognostic and response monitoring biomarkers, respectively, for SLIT \[[@B13]\]. Therefore, we analyzed the correlation of baseline cytokine levels and clinical efficacy. Our results found that baseline Th2 (IL-4, IL-5, and IL-13) and Th17 (IL-17) cytokines had no correlation with short-term efficacy, suggesting that Th1/Th2 imbalance was not reversed in the short term. Multivariate logistic regression analysis suggested baseline levels of IL-10 and IL-35 can predict clinical efficacy. Consistently, IL-35 and IL-10 can be induced by SLIT to play a protective role \[[@B15], [@B16]\]. Therefore, it is reasonable that higher baseline levels of IL-10 and IL-35 may predict good response of SLIT.

In summary, our results proved that the serum level of specific IgE (s-IgE), s-IgE/t-IgE ratio, IL-10, and IL-35 and the air conditioner use were significantly correlated with short-term efficacy of SLIT in children, which may be helpful for patient selection before SLIT.
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###### 

Baseline characteristics of 466 patients that underwent SLIT.

  --------------------------------------- ---------------------
  Age (years), mean ± SEM                 7.8 ± 2.5
  Male/female                             225/241
  Duration of symptoms (years)            4.2 ± 1.1
  Serum s-IgE level to Der f (IU/mL)^∗^   26.18 (10.73-68.81)
  Serum s-IgE/t-IgE ratio^∗^              11.5 (10.1-15.8)
  Response to SLIT                        303/466
  --------------------------------------- ---------------------

^∗^Geometric mean after logarithmic transformation (95% CI).

###### 

The reasons for the dropout of 51 children during SLIT.

  Reasons                                         Numbers
  ----------------------------------------------- ---------
  Lack of efficacy                                16
  Adverse events                                  13
  Fail to take medication according to schedule   10
  Loss to follow-up                               12
  Total                                           51

###### 

Adverse events during SLIT.

  Adverse events                    Numbers
  --------------------------------- ---------
  Aggravation of allergic symptom   21
  Local irritation symptom          15
  Gastrointestinal symptom          10
  Other minor symptom               19
  Total                             65

###### 

Clinical efficacy after short-term SLIT.

                         Effective group   Ineffective group
  ---------------------- ----------------- -------------------
  3 months of SLIT                         
   Cases                 271 (58%)         195 (42%)
   Endpoint symptoms     2.6 ± 1.2^∗^      6.5 ± 2.7
   Endpoint medication   3.7 ± 2.1^∗^      7.3 ± 3.6
   SMS                   7.8 ± 3.5^∗^      12.9 ± 4.3
  6 months of SLIT                         
   Cases                 303 (65%)         163 (35%)
   Endpoint symptoms     2.4 ± 1.1^∗^      6.7 ± 2.8
   Endpoint medication   3.1 ± 1.8^∗^      7.5 ± 3.4
   SMS                   6.9 ± 3.6^∗^      13.2 ± 4.6

^a^Data presented as median values (minimum-maximum). ^∗^Compared with the control group, *P* \< 0.05.

###### 

Univariate logistic analysis of factors associated with clinical response to SLIT.

  Characteristic                      Group                   *P* value             
  ----------------------------------- ----------------------- --------------------- -------
  Number (%)                          303 (65%)               163 (35%)             0.010
  Age (years)                         7.3 (6.1-9.2)           7.8 (6.3-9.5)         0.134
  Male (%)                            170 (56.1%)             96 (58.9%)            0.204
  BMI                                 22 (18.7-25.3)          21.5 (18.1-26.7)      0.363
  Diet habits (%)                                                                   
   Seafood                            21.5%                   20.3%                 0.181
   Poultry                            48.1%                   53.2%                 0.172
   Pork                               75.2%                   73.8%                 0.346
   Fast food                          12.1%                   11.6%                 0.067
   Beverages                          18.5%                   21.3%                 0.112
  Outdoor activities                                                                
   0-1 hour                           34%                     41%                   0.231
   1-2 hours                          42%                     41%                   0.135
   \>3 hours                          24%                     19%                   0.087
  Bedroom time                                                                      
   \<12 hours                         90%                     85%                   0.246
   \>12 hours                         10%                     15%                   0.417
  Living environment                                                                
   Bungalows/building                 5%/95%                  3%/97%                0.421
   Urban/rural area                   82%/18%                 85%/15%               0.653
   Atopic family history              57%                     68%                   0.512
   Pet raising                        8%                      5%                    0.214
   Plush toys (%)                     32%                     29%                   0.128
   Parental smoking (%)               65%                     59%                   0.119
  Education background (%)                                                          
   \<Master\'s degree                 38%                     48%                   0.013
   \>Master\'s degree                 62%                     52%                   0.024
  Air conditioning service time                                                     
   \<3 months/year                    21%                     10%                   0.006
   \>3 months/year                    79%                     90%                   0.008
  Bedding cleaning                                                                  
   \<1 time                           14%                     18%                   0.128
   \>1 time                           86%                     82%                   0.226
  Wall material                                                                     
   Wallpaper                          11%                     15%                   0.019
   Organic solvent coating            85%                     78%                   0.028
   Aqueous coating                    4%                      7%                    0.037
  Floor material                                                                    
   Carpet                             14%                     12%                   0.371
   Ceramic tile                       63%                     76%                   0.446
   Wood floor                         23%                     12%                   0.257
  Cooking fuel                                                                      
   Coal gas                           54%                     42%                   0.183
   Oil gas                            25%                     30%                   0.763
   Natural gas                        21%                     28%                   0.683
  Duration of disease                                                               
   \<1 year                           33%                     38%                   0.051
   1-2 years                          21%                     19%                   0.117
   \>3 years                          46%                     43%                   0.235
  Age of onset                        4 (3-6)                 4.5 (3-6)             0.411
  Severity                                                                          
   Mild                               23%                     25%                   0.371
   Moderate                           46%                     48%                   0.426
   Severe                             31%                     27%                   0.553
  t-IgE                               321.5 (178.5, 534)      413 (103, 852)        0.002
  IgG4                                10.4 (8.3, 11.8)        12.2 (10.9, 14.1)     0.226
  s-IgE of Der f                      27.7 (10.7, 68.8)       17.9 (7.3, 42.9)      0.001
  s-IgE/t-IgE ratios                  36.1 (21.7, 42.9)       17.8 (15.6, 21.4)     0.003
  Blood leukocyte count (×10^9^/L)    5.88 (5.03-7.53)        6.02 (5.18-7.88)      0.358
  Blood neutrophil count (×10^9^/L)   3.07 (2.53-3.85)        3.12 (2.68-4.05)      0.426
  Blood neutrophil percent (%)        49.1 (45.3-57.6)        47.8 (48.5-59.2)      0.189
  Blood lymphocyte count (×10^9^/L)   2.07 (1.69-2.78)        2.01 (1.71-2.65)      0.773
  Blood lymphocyte percent (%)        33.1 (29.5-42.8)        35.9 (28.7-44.6)      0.653
  Blood eosinophil count (×10^9^/L)   0.21 (0.13-0.48)        0.19 (0.11-0.38)      0.129
  Blood eosinophil percent (%)        3.65 (2.34-8.67)        2.97 (1.78-6.83)      0.137
  Blood monocyte count (×10^9^/L)     0.42 (0.35-0.56)        0.43 (0.33-0.59)      0.133
  Blood monocyte percent (%)          7.64 (6.34-9.81)        7.42 (6.15-8.95)      0.245
  Blood basophil count (×10^9^/L)     0.06 (0.03-0.11)        0.05 (0.04-0.10)      0.378
  Blood basophil percent (%)          1.03 (0.85-1.04)        0.98 (0.87-1.08)      0.198
  ECP (ng/mL)                         40.2 (5.6-128.4)        51.3 (7.8-145.1)      0.266
  IL-4 (pg/mL)                        3.4 (2.1-4.5)           3.8 (1.9-4.7)         0.098
  IL-5 (pg/mL)                        87.3 (45.8-137.8)       73.2 (41.6-119.5)     0.178
  IL-13 (pg/mL)                       1256.8 (783.1-1428.3)   1198.5 (68-1428.3)    0.264
  IL-12 (pg/mL)                       78.2 (52.1-124.6)       67.1 (41.9-117.8)     0.073
  IFN-*γ* (pg/mL)                     245.1 (178.3-301.6)     218.3 (166.4-285.0)   0.133
  IL-17 (pg/mL)                       124.5 (86.9-147.3)      137.8 (97.8-185.2)    0.187
  IL-10 (pg/mL)                       92.5 (71.3-101.6)       69.3 (63.1-80.1)      0.002
  IL-35 (pg/mL)                       187.3 (146.5-221.8)     106.2 (85.3-127.3)    0.001
  TGF-beta (pg/mL)                    192.1 (132.5-223.4)     187.6 (124.6-211.7)   0.004

Mean (95% CI). ^b^Geometric mean after logarithmic transformation (95% CI).

###### 

Multivariate logistic analysis of factors associated with clinical response to SLIT.

  Markers                             OR      95% CI        *P* value
  ----------------------------------- ------- ------------- -----------
  Parents\' educational background    3.478   1.251-6.095   0.13
  Materials for walls                 1.569   0.873-2.574   0.24
  Time of using the air conditioner   2.156   1.336-3.488   0.01
  t-IgE                               4.825   3.119-6.085   0.35
  s-IgE levels to Der f               2.673   1.983-3.249   0.01
  s-IgE/t-IgE ratios                  0.758   0.531-2.637   0.02
  IL-10                               1.239   0.642-2.745   0.03
  IL-35                               1.457   1.109-3.265   0.01
  TGF-beta                            0.875   0.668-2.188   0.07

###### 

Factors associated with clinical response to SLIT.

  Factors                             Correlation
  ----------------------------------- -------------
  Time of using the air conditioner   Negative
  s-IgE levels to Der f               Positive
  s-IgE/t-IgE ratios                  Positive
  IL-10                               Positive
  IL-35                               Positive
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